Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Amgen Inc.
  6. News
  7. Summary
    AMGN   US0311621009

AMGEN INC.

(AMGN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Amgen : A Special Edition of Innovation2, brought to you by David and Jim Reese (Brothers2)

10/20/2021 | 01:52pm EST

It's safe to say that family dinners at the Reese household were never boring. Dr. David Reese, executive vice president of Research and Development at Amgen, and his brother Dr. Jim Reese, former Chief Operations Engineer and employee #18 at Google and current advisory board member for Harvard Medical School Department of Biomedical Informatics, recently met up virtually to discuss their upbringing, personal inspirations and motivations as part of the latest installment of Innovation2.

In the video, both brothers shared the challenges they faced and overcame in their professional careers. Jim shared stories from his early days at Google, including what it took to scale the site from one room of servers to the behemoth search engine that we know today. Similarly, Dave shared his experience taking on drug development for some of the toughest-to-treat diseases, how memories from his days as a medical oncologist motivates him and what it takes to organize the "highly disciplined and specialized army" it takes to bring a drug to market.

Innovation2 is a video series created by Amgen in collaboration with The Nation of Artists to highlight how some of the brightest minds think about innovation. The series sheds light on what fuels tenacity for today's innovators and how pushing against the status quo allows them to truly make a difference in the world. Each episode features one innovator from within Amgen and one innovator from another sector. The conversations are often inspiring and entertaining, highlighting personal contributions and today's cutting-edge science and innovation.

You can view David and Jim's episode below, and the rest of the series is available on Amgen's YouTube channel.

Disclaimer

Amgen Inc. published this content on 20 October 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 20 October 2021 17:51:06 UTC.


ę Publicnow 2021
All news about AMGEN INC.
12/07CANDID CONVERSATIONS : Ability Bettered Through Leadership and Education (ABLE)
PU
12/07Amgen Announces New Data Being Presented At ASH 2021
AQ
12/06Amgen Announces New Data Being Presented At ASH 2021
CI
12/06Amgen on Pace for Largest Percent Increase Since November 2020 -- Data Talk
DJ
12/06Amgen Shares Rise After Goldman Sachs Begins Coverage at Buy
MT
12/06Goldman Sachs Starts Amgen at Buy With $258 Price Target
MT
12/06Amgen Announces 10% Increase in 2022 First Quarter Dividend
AQ
12/03AMGEN : Bradway Hails Amgen's Progress Against 'Undruggable' Disease Targets at Two Health..
PU
12/03Amgen Raises Fiscal Q1 Dividend 10% to $1.94 a Share, Payable March 8 to Shareholders o..
MT
12/03Amgen Announces 10% Increase In 2022 First Quarter Dividend
PR
More news
Analyst Recommendations on AMGEN INC.
More recommendations
Financials (USD)
Sales 2021 26 019 M - -
Net income 2021 5 551 M - -
Net Debt 2021 22 522 M - -
P/E ratio 2021 21,3x
Yield 2021 3,30%
Capitalization 119 B 119 B -
EV / Sales 2021 5,44x
EV / Sales 2022 5,14x
Nbr of Employees 24 300
Free-Float 99,8%
Chart AMGEN INC.
Duration : Period :
Amgen Inc. Technical Analysis Chart | AMGN | US0311621009 | MarketScreener
Technical analysis trends AMGEN INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Last Close Price 211,32 $
Average target price 239,73 $
Spread / Average Target 13,4%
EPS Revisions
Managers and Directors
Robert A. Bradway Chairman, President & Chief Executive Officer
Peter H. Griffith Chief Financial Officer & Executive Vice President
David M. Reese Executive Vice President-Research & Development
Darryl Sleep Chief Medical Officer & Senior VP-Global Medical
Mike Zahigian Chief Information Officer & Senior Vice President
Sector and Competitors
1st jan.Capi. (M$)
AMGEN INC.-8.09%119 029
JOHNSON & JOHNSON3.80%430 061
ROCHE HOLDING AG19.17%324 115
PFIZER, INC.39.85%290 297
NOVO NORDISK A/S70.26%250 392
ELI LILLY AND COMPANY45.17%222 215